Abstract
Objective Several studies have found thinner retinal tissue in mental disorders compared to healthy controls. Because the retina is part of the human brain, this suggests that informative brain structure readouts can be obtained efficiently through retinal imaging. Instead of focusing on group-level case-control differences, we used normative modeling to estimate age-related decline of the human retina (and its expected variation) and compared it to the decline seen in schizophrenia (SZ), bipolar disorder (BD), and major depression (MDD). We hypothesized accelerated retinal decline in mental disorders compared to controls, with SZ being most affected, followed by BD, then MDD.
Methods Using UK Biobank data, we estimated age-related retinal decline in healthy controls (HC, N = 56,545) for total macular thickness (including coronal subfields) and two sublayers (retinal nerve fiber layer; RNFL; and ganglion cell-inner plexiform layer; GC-IPL). We then compared the decline in SZ (N = 171), BD (N = 256), and MDD (N = 102) to the normative decline in HC.
Results For HC, the pattern of age-related decline for total macular thickness, RNFL, and GC-IPL was curve-like rather than linear and more pronounced in males compared to females. For mental disorders, the decline-pattern was generally faster, driven by SZ and disorder-specific macular subfields. There was also an enrichment of individuals with extremely low (infranormal) values. These results were confirmed in robustness checks that ruled out unspecific confounders.
Conclusion These findings suggest that mental disorders, particularly SZ, involve accelerated neurodegenerative decline that can be detected in the human retina.
Competing Interest Statement
PH has received grants and honoraria from Novartis, Lundbeck, Takeda, Mepha, Janssen, Boehringer Ingelheim, Neurolite and OM Pharma outside of this work. No other conflicts of interest were reported.
Funding Statement
This work was supported by a NARSAD grant from the Brain & Behavior Research Foundation (28445, to PH), by a Research Grant from the Novartis Foundation (20A058, to PH) and by an ERC Synergy Grant (101118756, to PH), and a research grant from the Hans and Marianne Schwyn Foundation (230273, to FG).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This version of the manuscript has been revised to expand the original analysis, comparing disorder groups directly at multiple levels and by adding multiple robustness checks of the original analysis.
Data Availability
All data utilized in this study is publicly available at the UK Biobank (http://www.ukbiobank.ac.uk/). All code will be made freely available after publication to ensure reproducibility at https://github.com/homanlab
